Expanded access, the system through which the FDA provides access to investigational drugs outside of clinical trials, was designed for patients who have no known effective treatment options for serious diseases or conditions. There is a delicate balance between helping desperately ill people access treatments that could be potentially beneficial in a timely manner and ensuring that the benefits of the treatments outweigh the risks to the patient.
In addition to the expanded access program, legislative actions have been passed at both the federal and state level, including "right-to-try" laws and the 21st Century Cures Act, which help provide access to investigational drugs without needing to go through the FDA process.
Read this whitepaper to learn more about expanded access and right-to-try and the complexity of giving patients access to investigational drugs.
Recent Insights
»
Whitepapers
»
Investigational Drugs Outside of Clinical Trials - Understanding Expanded Access and Right-to-Try
Most Recent Flipbooks

Targeted expertise when and where you need it: WCG CRCs equip sites to navigate the new normal
Save the Data. Protect the Patients. Prepare for What Comes Next: Remote Clinical Research Coordinators
Clinical Research Trends & Insights for 2020
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.

The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design

Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk

Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials

Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines

Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting

Part 4: Planning for Recovery: How Research Sponsors and Research Sites are Thinking Ahead to Restart Research